Abstract
We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Current Drug Therapy
Title: Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Volume: 4 Issue: 1
Author(s): Khaled El-Meniawy, Hanan Hafez, Hala Bamatraf and Wail Nammas
Affiliation:
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Abstract: We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Export Options
About this article
Cite this article as:
El-Meniawy Khaled, Hafez Hanan, Bamatraf Hala and Nammas Wail, Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081822
DOI https://dx.doi.org/10.2174/157488509787081822 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews Electrochemical-Based Biosensors: New Diagnosis Platforms for Cardiovascular Disease
Current Medicinal Chemistry Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Editorial (Thematic Issue: Novel Therapeutic Strategies for Cardiovascular Disease Treatment: From Molecular Level to Nanotechnology)
Current Pharmaceutical Design Identification of Important Positions within miRNAs by Integrating Sequential and Structural Features
Current Protein & Peptide Science The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Iodinated Contrast Media in Diagnostic Imaging: Cardiovascular Side Effects
Current Pharmacogenomics and Personalized Medicine The Role of Nitro (NO<sub>2</sub>-), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds
Current Drug Targets Role of Chymase in Preeclampsia
Current Vascular Pharmacology Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Current Pharmaceutical Design Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry